Fortis Healthcare Ltd (FORTIS) is currently trading at 875.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Fortis Healthcare is a leading integrated healthcare delivery provider in India operating 36 facilities across 12 states with over 6,000 operational beds (including O&M) and a large diagnostics franchise, offering multi‑specialty and quaternary services across Cardiac, Oncology, Neuro, Renal and other specialties under an integrated hospital and diagnostics model. Q3 FY26 results show healthy top‑line and margin expansion: consolidated revenue grew 17.5% YoY to INR 2,265 Cr while operating EBITDA rose 34.8% to INR 505 Cr with a 22.3% margin; hospital revenues grew 19.4% and hospital EBITDA margin expanded to 21.7%, signaling improving operating leverage at Fortis Healthcare. Diagnostics under Agilus is improving materially with gross revenues of INR 371 Cr, 9.9 million tests in the quarter, network expansion to 4,370 customer touchpoints and a meaningful margin step‑up driven by automation, specialized tests and higher preventive portfolio contribution; Fortis Healthcare has also scaled NGS capability via Illumina NovaSeq X to bolster high‑throughput genomics. Fortis Healthcare is executing a cluster‑based inorganic strategy: the Jan’26 People Tree Bengaluru acquisition (125 beds, expandable to 300) and other acquisitions plus brownfield projects (FMRI tower, Manesar, Noida expansions) added ~750 beds YTD and pushed net debt to INR 2,547 Cr, reflecting deliberate balance‑sheet deployment to accelerate scale across existing clusters. Margin concentration is notable: 13 facilities delivered >20% EBITDA and accounted for ~77% of hospital revenues in 9MFY26, while digital channels contribute ~30% of hospital revenue; Fortis Healthcare is leveraging specialty clustering, digital channels, and high‑value case mix (robotic and complex surgeries) to drive ARPOB and margins.

Over the past 52 weeks, Fortis Healthcare Ltd has traded between a low of ₹767.30 and a high of ₹1,105.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Fortis Healthcare Ltd has a market capitalization of approximately 66,058.84. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Fortis Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 61.73 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 66,058.84 Cr, Fortis Healthcare Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Fortis Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Fortis Healthcare Ltd is 61.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Fortis Healthcare is scheduled to announce its Q1 FY27 (June quarter) financial results on August 6, 2026, following a board meeting to approve the unaudited numbers.

Fortis Healthcare reported FY26 consolidated revenue from operations of ₹9,127.84 crore and profit for the year of ₹1,064.19 crore.

Officials said a complaint during a CM public hearing alleged delayed emergency treatment and a demand for money before care, leading to an inspection that flagged multiple discrepancies.

Fortis reported Q4 FY26 revenue from operations of ₹2,365 crore and PAT of ₹271 crore, compared with ₹2,007 crore revenue and ₹188 crore PAT in Q4 FY25.